KRAS and colorectal carcinoma: In addition to a wide spectrum of cancer models, including glioblastoma (Ugolkov et al., 2017), pancreatic (Ding et al., 2017), breast (Ugolkov et al., 2016), and bladder (Kuroki et al., 2019) cancers, 9-ING-41 has already been tested on wild-type KRAS CRC cell line HT-29 (Poloznikov et al., 2019) and recently on a panel of CRC cell lines (Huntington et al., 2021).